Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00931710 · ClinicalTrials.gov registry record · Phase 4
Valsartan/Amlodipine As Compared to Losartan Treatment in Stage 2 Systolic Hypertension
A Phase 4 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 4
- Development phase
- 488
- Enrollment target
NCT00931710 is a Phase 4 study that has completed, run by Novartis. The registered enrollment target is 488 participants.
The verdict
NCT00931710, a Phase 4 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 488 participants
- Enrollment target
Study Summary
This study will compare the antihypertensive efficacy and safety of a valsartan/amlodipine-based treatment with a losartan-based treatment in patients with Stage 2 systolic hypertension (high blood pressure, mean systolic blood pressure greater than 160 and less than 200 mmHg).
Interventions
- DRUG valsartan, amlodipine, HCTZ
- DRUG Losartan, HCTZ followed by valsartan, amlodipine, HCTZ
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 488 participants |
| Start Date | 2009-07 |
| Est. Completion | 2010-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00931710
The ClinicalTrials.gov registry entry for NCT00931710 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 488 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which valsartan, amlodipine, HCTZ is the first listed.
NCT00931710 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00931710 about?
NCT00931710 is a clinical study titled "Valsartan/Amlodipine As Compared to Losartan Treatment in Stage 2 Systolic Hypertension". This study will compare the antihypertensive efficacy and safety of a valsartan/amlodipine-based treatment with a losartan-based treatment in patients with Stage 2 systolic hypertension (high blood pressure, mean systolic blood pressure greater than 160 and less than 200 mmHg).
What is the current status of trial NCT00931710?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 488 participants. The study started on 2009-07. Estimated completion is 2010-01.
What interventions are being tested in trial NCT00931710?
The interventions under investigation include: valsartan, amlodipine, HCTZ (DRUG), Losartan, HCTZ followed by valsartan, amlodipine, HCTZ (DRUG).
Who is sponsoring clinical trial NCT00931710?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.